



## Press release

### **Orexo publishes prospectus and applies for listing of bonds on Nasdaq Stockholm**

**Uppsala, Sweden – November 30, 2017** – On 31 October 2017, Orexo AB (publ) (the “**Company**”) announced that the Company successfully had issued a four-year senior unsecured bond loan in an amount of SEK 325 million, within a framework amount of SEK 500 million, and a floating interest rate of STIBOR 3m +4.50 per cent per year (quarterly payments in arrears).

The Company intends to list the bonds on the corporate bond list of Nasdaq Stockholm. In connection therewith, the Company has prepared a prospectus which has been approved by the Swedish Financial Supervisory Authority. First day for trading in the bonds on Nasdaq Stockholm is expected to be 1 December 2017.

The prospectus is available on the Swedish Financial Supervisory Authority’s website ([www.fi.se](http://www.fi.se)) and on Orexo’s website ([www.orexo.com](http://www.orexo.com)) and will also be sent to those who so request.

#### **For further information, please contact:**

##### **Orexo AB (publ.)**

Henrik Juuel, EVP and CFO

Tel: +46 (0)18 780 88 00

E-mail: [ir@orexo.com](mailto:ir@orexo.com)

Lena Wange, IR & Communications Manager

Tel: + 46 (0)18 780 88 00

E-mail: [ir@orexo.com](mailto:ir@orexo.com)

#### **About Orexo**

Orexo develops improved pharmaceuticals based on innovative drug delivery technologies. The focus is primarily on opioid dependence and pain but the aim is to address therapeutic areas where our competence and technologies can create value. The main market today is the US market for the treatment of opioid dependence where the product Zubsolv® is commercialized by Orexo. Other products are commercialized by license partners, including Zubsolv in markets outside of the US. Total net sales for 2016 amounted to SEK 705.9 million and the number of employees was 102. Orexo is listed on the Nasdaq Stockholm Mid Cap (ORX) index and is available as ADRs on OTCQX (ORXOY) in the US. The head office, where also research and development is performed, is located in Uppsala, Sweden.



For more information about Orexo please visit, [www.orexo.com](http://www.orexo.com). You can also follow Orexo on Twitter, @orexoabpubl, LinkedIn and YouTube. For more information about Zubsolv in the US, see the product and market websites [www.zubsolv.com](http://www.zubsolv.com) and [www.rise-us.com](http://www.rise-us.com).

The information was submitted for publication at 8:30 am CET, November 30, 2017